Lipid Conjugates for Selective Adipose Oligonucleotide Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing technologies face challenges in delivering oligonucleotide-based agents, such as RNAi agents, selectively and effectively to adipose tissue due to non-specific distribution and toxicity concerns with current delivery methods.
Innovation Solution
Development of lipid conjugates that facilitate the delivery of oligonucleotide-based agents to adipose tissue by conjugating lipids to the terminal or internal nucleotides of oligonucleotides, enhancing pharmacokinetic and pharmacodynamic properties for targeted delivery to adipose cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cholesterol conjugates are used to deliver oligonucleotide-based agents to extra-hepatic cells, then delivery to target cells is achieved, but non-specific distribution to various undesired tissues and organs occurs
Solution Approach 1:
The patent applies local quality by designing lipids with specific local structural features (unsaturation, chain length, functional groups) that confer selective recognition by adipose tissue. The lipid structure is optimized locally at the conjugation site to interact specifically with adipose tissue components while avoiding non-specific binding to other tissues.
Solution Approach 2:
The patent employs parameter changes by systematically varying lipid properties including degree of unsaturation (one or two double bonds), chain length (C12-C30), and functional group composition to achieve optimal specificity for adipose tissue. These parameter optimizations distinguish the invention from cholesterol conjugates that lack such controlled variations.
2Reliability
If lipid-nanoparticles (LNPs) are used to deliver oligonucleotide-based agents, then delivery capability is provided, but non-specific distribution and toxicity concerns arise
Solution Approach 1:
The patent extracts and eliminates the problematic nanoparticle carrier component, using only the lipid conjugate itself as the delivery vehicle. This removes the source of non-specific distribution and toxicity associated with LNPs while retaining the essential lipid-mediated delivery function.
Solution Approach 2:
The lipid conjugate acts as an intermediary between the oligonucleotide agent and adipose tissue, providing specific molecular recognition and targeted delivery without the non-specific effects of nanoparticle carriers. The lipid structure serves as a precise mediator that bridges the therapeutic agent and target tissue.
3Productivity
If conventional delivery methods are used for oligonucleotide-based agents, then general delivery is achieved, but selective and effective delivery to adipose tissue is not realized
Solution Approach 1:
The patent segments the delivery system into distinct functional components: the oligonucleotide therapeutic agent and the specifically designed lipid conjugate. This segmentation allows independent optimization of each component, with the lipid portion engineered specifically for adipose tissue targeting while the oligonucleotide maintains its therapeutic function.
Data Source
AI summary
Disclosed herein are compounds comprising lipid PK/PD modulators for delivery of oligonucleotide-based agents, e.g., double stranded RNAi agents or antisense oligonucleotides, to certain tissues (e.g., adipose tissue) or cell types (e.g., adipocytes) in vivo. The PK/PD modulators disclosed herein, when conjugated to an oligonucleotide-based therapeutic or diagnostic agent, such as an RNAi agent, can enhance the delivery of the composition to the adipocytes in vivo to facilitate the inhibition of gene expression in those cells.